Figure 4.

Enhanced activation of lymphocytes in imiquimod-treated Fcrl5 Tg mice. (A) Absolute number of splenocytes, CD19⁺, CD8⁺, and CD4⁺ in spleen from imiquimod-untreated (IMQ–) WT (n=9) and Fcrl5 Tg (n=9) or -treated (IMQ+) WT (n=13) and Fcrl5 Tg (n=14) mice. Data are pooled from three independent experiments. (B) Representative flow cytometry plots and absolute numbers of CD23^–CD21^lo (CD19⁺CD93^–CD23^–CD21^lo), FO B (CD19⁺CD93^–CD23⁺CD21^lo), and MZ B (CD19⁺CD93^–CD23^–CD21^hi) cells from imiquimod-untreated (IMQ–) WT (n=9) and Fcrl5 Tg (n=9) or -treated (IMQ+) WT (n=13) and Fcrl5 Tg (n=14) mice. Data are pooled from three independent experiments. (C) Top, representative flow cytometry plots, frequencies, and absolute numbers of GC B (B220⁺Fas⁺GL7⁺) cells from imiquimod-untreated (IMQ–) WT (n=9) and Fcrl5 Tg (n=9) or -treated (IMQ+) WT (n=13) and Fcrl5 Tg (n=14) mice. Bottom, representative flow cytometry plots and absolute numbers of ABCs (CD19⁺B220^hiCD23^–CD21^loCD11b⁺CD11c⁺) from imiquimod-untreated (IMQ–) WT (n=6) and Fcrl5 Tg (n=6) or -treated (IMQ+) WT (n=10) and Fcrl5 Tg (n=7) mice. Data are pooled from two or three independent experiments. (D) Representative flow cytometry plots (left) and absolute numbers (right) of CD4⁺ T cell subsets: effector T (CD4⁺CD25^–CD62L^–CD44^hi), Tfh (CD4⁺CXCR5⁺PD-1⁺), Treg (CD4⁺CD25⁺Foxp3⁺), CD4⁺IFN-γ⁺, and CD4⁺IL-2⁺ cells from imiquimod-untreated (IMQ–) WT (n=6–9) and Fcrl5 Tg (n=6–9) or -treated (IMQ+) WT (n=6–13) and Fcrl5 Tg (n=7–14) mice. Data are pooled from two or three independent experiments. Statistical data are shown as mean values with s.d., and data were analyzed by one-way ANOVA with Tukey’s multiple comparisons test (A–D) or Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test (C). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.